Waystar Considers Strategic Options, Including Potential Sale

Waystar, a prominent player in healthcare software known for automating administrative tasks for hospitals and doctors, is evaluating strategic alternatives, including a potential sale. This move comes just two years after the company went public in New York. Seven sources familiar with the situation have indicated that Waystar has enlisted investment bank Evercore to guide the process, which remains in its early stages.

The company, which operates out of Lehi, Utah, and Louisville, Kentucky, has seen its market value dip to approximately $4.8 billion following a 24% decrease in share price this year. This decline is part of a broader downturn affecting the software sector. Despite these challenges, an auction process may reveal whether investor interest in software firms is making a comeback.

Focus on Technology-Driven Valuation

Waystar has strategically positioned itself as a technology company rather than a service-oriented business. By focusing on selling solutions that automate administrative work, the company aimed to achieve the higher valuations typically associated with tech firms. Initially, this strategy was well-received, with shares climbing from $20 to a peak of $45 in 2025. However, investor sentiment shifted as concerns grew over potential disruptions from advancements in artificial intelligence, as noted by Morgan Stanley analysts in a July report.

Background and Ownership Structure

Formed in 2017 through the merger of Zirmed and Navicure, Waystar has attracted significant investment from major backers. The company's largest shareholders include EQT with a 13% stake, the Canada Pension Plan Investment Board (CPPIB) holding 10%, and BlackRock Institutional Trust Company owning 8%, according to LSEG data. These stakeholders played a pivotal role in taking Waystar public in 2024.

Representatives from EQT and BlackRock have declined to comment on the current proceedings, while CPPIB has yet to respond to inquiries. Evercore, tasked with advising Waystar on its strategic options, also did not immediately provide a statement.

Market Context and Future Prospects

Waystar's exploration of a sale or other strategic paths highlights the volatility and competitive pressures within the software industry. As the market grapples with technological advancements and shifting investor priorities, companies like Waystar are reassessing their positions and long-term strategies. Whether this process will culminate in a sale or another outcome remains uncertain, but it underscores the dynamic nature of the healthcare software sector.